- Tytuł:
- Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system
- Autorzy:
- Źródło:
- BMC Health Services Research. 10/11/2023, Vol. 23 Issue 1, p1-13. 13p. 1 Diagram, 4 Charts, 3 Graphs.
Czasopismo naukowe